Modulators of rituximab-induced complement-dependent cytotoxicity in diffuse large B-cell lymphoma
Rituximab, the chimeric monoclonal antibody targeting CD20, forms the cornerstone of therapy for diffuse large B-cell lymphoma (DLBCL). However, more than one-third of patients eventually become unresponsive or resistant to rituximab. Although the mechanisms of action and resistance are not well und...
Autor principal: | |
---|---|
Outros Autores: | |
Formato: | Final Year Project (FYP) |
Idioma: | English |
Publicado em: |
Nanyang Technological University
2021
|
Assuntos: | |
Acesso em linha: | https://hdl.handle.net/10356/149717 |